Background. The risk of second bacteremia during antibiotic treatment for initial bacteremia is unknown in high-risk populations. Our objectives were to describe the prevalence of second bacteremia during treatment and identify risk factors in children with acute myeloid leukemia (AML). Methods. We conducted a retrospective, population-based cohort study that included children and adolescents with de novo, non-M3 AML who were diagnosed and treated between January 1, 1995 and December 31, 2004 at 15 Canadian centers. Patients were monitored for bacteremia during chemotherapy until completion of treatment, hematopoietic stem cell transplantation, relapse, refractory disease, or death.
INTRODUCTION
Acute myeloid leukemia (AML) comprises 15%-20% of all acute leukemias in children and adolescents, but accounts for a disproportionate 30% of death among cases [1] . Intensification of chemotherapy, refinement in risk classification, new insight into the biology and improvement in supportive care have increased survival rates from <20% in the 1970s to approximately 70% in the current era [2, 3] . Despite major improvements in outcomes, infection remains an important cause of morbidity and mortality among children with AML. Different cooperative groups have reported infection-related mortality rates ranging from 5.4% to 11.0% from invasive bacterial and fungal infections [4, 5] . Among 492 children with AML enrolled in Children's Cancer Group 2961, more than 60% experienced microbiologically documented infection during each chemotherapy course [5] . Gram-positive bacteremias, particularly coagulase-negative Staphylococcus (CoNS) and viridans group streptococci (VGS), were the most common etiologic agents leading to infectious deaths [5] .
Consequently, identification of an infectious pathogen associated with fever and neutropenia (FN) is common in AML. The 2010 Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer by the Infectious Diseases Society of America (IDSA) recommended that modifications to the initial empiric antibiotic regimen should be guided by the identification of clinically or microbiologically documented infection and antimicrobial susceptibility data [6] . This guideline, along with the recommendations from the Fourth European Conference on Infections in Leukemia, also suggested that the antibiotic spectrum could be narrowed to treat the specific infection once fever has resolved [6, 7] . However, this practice has raised many questions among experts in FN in terms of the management of high-risk FN with a microbiologically documented source of fever, particularly in the setting of defervescence with appropriate treatment.
In order to address this question, it may be instructive to evaluate the risk of second invasive bacterial infection in children with AML and documented bacteremia as the cause of initial fever. The primary objective of our study was to describe the prevalence of second bacteremia during antibiotic treatment for initial bacteremia in children with AML. The secondary objective was to identify risk factors for second bacteremia.
PATIENTS AND METHODS
In this retrospective, population-based cohort study, we included children with newly diagnosed AML who developed bacteremia during their treatment course. This manuscript is a follow-up analysis of a larger study in which all infectious outcomes (microbiologically documented sterile site infection, clinically documented infection, sepsis, and fever of unknown origin) of children with newly diagnosed AML in Canada were analyzed [8] .
Study Sample
We included children and adolescents with de novo AML who were diagnosed between January 1, 1995 and December 31, 2004 at one of the 15 Canadian centers that care for children with cancer in each province except Saskatchewan. Children with Down syndrome were included. We excluded those with acute promyelocytic leukemia, secondary AML, previous diagnosis of immunodeficiency, and children with Down syndrome receiving only low-dose cytarabine. This analysis focused on those who developed bacteremia during their treatment.
Procedures
Evaluation for bacteremia continued until one of the following events occurred: hematopoietic recovery from the last cycle of chemotherapy, start of conditioning for hematopoietic stem cell transplantation, relapse, change in protocol therapy due to refractory disease, or death (whichever occurred first). Bacteremia with common contaminants such as CoNS was only considered true infection if there were two or more positive cultures within the same episode or if the infection was associated with sepsis [9, 10] . Sepsis was defined as systemic inflammatory response syndrome in the presence of suspected or proven infection and organ dysfunction according to international consensus guidelines [11, 12] . Trained clinical research associates travelled to each site to abstract and code the relevant information.
Outcome and Potential Predictors
The primary outcome of this study was the occurrence of second bacteremia with a different organism while receiving antibiotic treatment for an initial bacteremia. These were identified by first evaluating any bacteremia occurring within 30 days of a previous bacteremia. Then, the records were inspected to determine whether the child was still receiving treatment for the initial bacteremia. Only second bacteremias within the same neutropenic period were included. We described demographic characteristics of patients who had any bacteremia during their treatment course and those who developed second bacteremia on treatment. In addition, the following patient and course characteristics were evaluated to determine whether they were associated with the occurrence of second bacteremia on treatment: age at diagnosis; obesity; diagnosis before January 1, 2000 (to evaluate change over time); cumulative dose of cytarabine in grams/m (threshold chosen a priori); number of days during which systemic corticosteroids were administered for any reason; cumulative dose of corticosteroids ( presented as per 10 mg/m 2 dexamethasone equivalents); number of days between start of course; and initial bacteremia and number of days of neutropenia during this period. Obesity was defined as a body mass index percentile 95% for age and gender according to the Centers for Disease Control and Prevention for those at least 2 years of age [13] . Neutropenia was defined as an absolute neutrophil count 500 cells/µL. Fever was defined as an oral temperature 38.3°C once or 38.0°C twice over 12 hours. Broadspectrum antibiotics included any regimen recommended by the IDSA guidelines appropriate for the empiric treatment of high-risk FN [6] .
Statistics
Factors associated with the occurrence of second bacteremia on treatment were examined using a repeated measures logistic regression with generalized estimating equations, and the association was expressed as an odds ratio (OR) with 95% confidence interval (CI). One patient had 3 consecutive bacteremias during 1 episode and thus had 2 second bacteremias. As a sensitivity analysis, we repeated all analyses including only 1 second bacteremia for each episode. Given the number of second bacteremia, multiple regression was not performed. All tests of significance were two-sided, and statistical significance was defined as P < .05. Statistical analysis was performed using the SAS statistical program (SAS-PC, version 9.3; SAS Institute Inc., Cary, NC).
RESULTS
The primary AML study included 341 patients; there were 290 episodes of bacteremia occurring in 185 (54.3%) children [8] . Among the 290 episodes of bacteremia, 31 (10.7%) had a second bacteremia within 30 days and 18 (6.2%) had a second bacteremia with a different organism while on antibiotic treatment for the initial bacteremia. The patient and course characteristics of all episodes of bacteremia and second bacteremia on antibiotic treatment are shown in Table 1 . Table 2 provides a detailed description for each of the 18 episodes of second bacteremia on treatment and includes the following elements: organisms isolated from the initial and second bacteremia, antibiotic regimen started with the first episode of FN of the chemotherapy course, antibiotic regimen 1 day before the second bacteremia (in other words, antibiotic regimen when second bacteremia developed), days between the initial and second bacteremia, days of continuous fever before the second bacteremia, and days of neutropenia and broad-spectrum antibiotics from start of course to second bacteremia.
Among the 18 episodes of second bacteremia, the first organism was Gram positive in 9 (50%) episodes with VGS being the most common. The first organism was Gram negative in the remaining 9 episodes with Escherichia coli being the most common. Organisms identified in the second bacteremia were of diverse species. The second bacteremia was Gram positive in 11 (61.1%) episodes with CoNS being the most common, whereas the second bacteremia was Gram negative in 7 (38.9%) episodes with Enterobacter cloacae being the most common. Among the 18 episodes of second bacteremia on treatment, 11 episodes (61.1%) had either an initial Grampositive and subsequent Gram-negative bacteremia or vice versa. Two of the 18 second bacteremia were complicated by sepsis with E. cloacae and Pseudomonas aeruginosa.
Four of the 7 Gram-negative second bacteremia organisms were resistant to either meropenem and/or piperacillin. Narrowing of antibiotics to a combination that would not be appropriate for the empiric management of FN occurred in 2 episodes. In 1 episode, the empiric broad-spectrum antibiotic regimen was narrowed from piperacillin-gentamicin to cefotaxime-gentamicin following defervescence. This Missing for n = 6 patients in bacteremia cohort. c Missing for n = 9 patients in bacteremia cohort and n = 1 patient in second bacteremia cohort. change was followed by multidrug-resistant P. aeruginosa in the second bacteremia. In a second patient, the empiric piperacillin-tobramycin-cloxacillin regimen was changed to vancomycin-tobramycin upon identification of the initial bacteremia with VGS, which was followed by 2 subsequent bacteremias during antibiotic treatment 5 and 7 days after the initial bacteremia with Fusobacterium spp. and Capnocytophaga spp., respectively.
All episodes of second bacteremia occurred within 14 days (mean ± standard deviation 6.0 ± 3.8 days) from the initial bacteremia. In 11 episodes, there was 1 or more days of continuous fever before the second bacteremia, whereas in 7 episodes the second bacteremia was associated with new fever without preceding days of fever. In 11 episodes, there was more than 15 days of neutropenia from the start of the course until the second bacteremia. Table 3 illustrates factors associated with second bacteremia during antibiotic treatment. Days receiving corticosteroids (OR, 1.09; 95% CI, 1.07-1.12; P < .0001), cumulative dose of corticosteroids (OR, 1.04; 95% CI, 1.00-1.08; P = .035), and days of neutropenia from start of course to initial bacteremia (OR, 1.07; 95% CI, 1.02-1.12; P = .007) were significantly associated with an increased risk of developing second bacteremia on treatment. In the sensitivity analysis, in which only 1 second bacteremia per episode was included among 17 episodes, the results were almost identical (data not shown).
DISCUSSION
We found that 6.2% of bacteremia episodes in pediatric AML were followed by a second bacteremia with a different organism while receiving antibiotic treatment for the initial bacteremia. Number of days receiving corticosteroids, cumulative dose of corticosteroids, and number of days of neutropenia from start of course to initial bacteremia were risk factors for developing second bacteremia.
We found that days receiving corticosteroids and cumulative dose of corticosteroids significantly increased the risk of developing second bacteremia on antibiotic treatment. This finding is consistent with the observation from the parent study in which the duration of corticosteroid exposure was the most significant risk factor associated with infection, sepsis, and infectious death in children with AML [8] . Our study provides further rationale for minimizing corticosteroid exposure whenever possible in this population. We also found that days of neutropenia from the start of the chemotherapy course to the first bacteremia increased the risk of developing second bacteremia on antibiotic treatment. This variable may identify children with more profound and prolonged neutropenia. Although duration of neutropenia >15 days was not a significant risk factor, the point estimate of an OR of 5.45 supports this hypothesis.
We observed that approximately 1 in 20 bacteremia episodes was followed by a second bacteremia while still receiving antibiotic treatment and that the majority of second bacteremia were of the opposite Gram stain type compared with the initial bacteremia. These findings suggest that even if an initial microbiological cause of fever is identified and even if fever resolves with appropriate antibiotic treatment, these children continue to be at risk for further invasive bacterial infection during the episode of profound neutropenia. We cannot estimate the effect of narrowing antibiotics to organism-specific treatment in this setting because most of the children in our cohort continued with broad-spectrum antibiotic therapy. However, we did observe 2 instances in which antibiotic narrowing was followed by second bacteremia. Although our data do not entirely address the ambiguity of the IDSA guidelines in regards to antibiotic narrowing after identification of a microbiologically documented infection, the data provide additional evidence that these patients remain at high risk for developing a second bacteremia during periods of profound neutropenia. Therefore, it may be reasonable to continue broad-spectrum antibiotic therapy in profoundly neutropenic children with an identified microbiological cause of fever. When criteria to discontinue broad-spectrum antibiotics are met [14] , it would then be sensible to narrow the spectrum of coverage if ongoing antibiotic therapy is required to treat the microbiologically documented infection. However, such an approach needs to carefully balance the potential benefit of continued broad-spectrum antibiotics against the risk of developing atypical and more resistant pathogens. Further data are required to address the controversy of antibiotic narrowing in the setting of documented bacteremia during FN.
Our study has unique strengths. To the best of our knowledge, this is the first report to examine the occurrence of second bacteremia with a different organism on antibiotic treatment and its associated risk factors among children with AML. This knowledge is important and relevant for clinicians who care for these children because it can guide specific supportive care measures, particularly around the use of broad-spectrum antibiotics and avoidance of corticosteroids. The population-based design of this analysis, comprehensive evaluation of infectious outcomes, careful exclusion of contaminants, and rigorous data extraction by trained research associates allow for an accurate estimate of the incidence of second bacteremia. However, this report also has important limitations. The results require careful interpretation given its retrospective nature and the heterogeneity of supportive care guidelines between involved institutions. The cohort included patients diagnosed between 1995 and 2004, and antibiotic resistance patterns and supportive care practices may have changed over time. Furthermore, the sample was restricted to children treated at Canadian hospitals, and there may be important variability based on geographic considerations. Also, another limitation of our study lies in the fact that the association between corticosteroid exposure and the risk of second bacteremia may be confounded by the indication for the corticosteroid. Finally, because the indication for blood cultures was not standardized, there is the possibility of selection and ascertainment bias.
In conclusion, second bacteremia on antibiotic treatment occurred in 6.2% of all initial bacteremia episodes among children with AML. Duration of corticosteroid exposure, cumulative dose of corticosteroids, and duration of neutropenia significantly increased the risk of developing second bacteremia on treatment. In light of these findings, we suggest avoidance of corticosteroid exposure when possible during AML therapy and continuation of broad-spectrum antibiotic coverage for documented bacteremia during profound neutropenia until criteria for empiric antibiotic therapy discontinuation are met. Prophylactic antibiotic strategies, either at onset of neutropenia or after recovery from an identified organism, warrant investigation in this setting.
